PMID- 35638425
OWN - NLM
STAT- MEDLINE
DCOM- 20220602
LR  - 20220611
IS  - 2768-6698 (Electronic)
IS  - 2768-6698 (Linking)
VI  - 27
IP  - 5
DP  - 2022 May 16
TI  - Circulating Microvesicles in Convalescent Ischemic Stroke Patients: A Contributor 
      to High-On-Treatment Residual Platelet Reactivity?
PG  - 158
LID - 10.31083/j.fbl2705158 [doi]
AB  - INTRODUCTION: Exploration of novel and effective antiplatelet strategies for the 
      secondary prevention of ischemic stroke is utmost. Some platelet derived 
      microparticles (PMVs) in convalescent stroke subjects were found to be predictive 
      for the next vascular event. Patients with high-on-treatment platelet reactivity 
      (HTPR) had a significantly higher risk for ischemic stroke. Here, we aimed to 
      explore associations among circulating microparticles and responsivness to 
      antiplatelet (clopidogrel) therapy. METHODS: A total of 18 patients on 
      clopidogrel therapy due to secondary stroke prevention were rospectively 
      recruited into this study. Twenty age-matched healthy subjects served as 
      controls. Flow cytometric measurements of microparicles (MVs) and data analysis 
      were performed on Beckman-Coulter FC-500 cytometer with CXP software. Besides, 
      platelet aggregometry data were revealed. Both measurements were performed in 
      whole blood and from the lower and upper blood fractions separated after 1-hour 
      gravity sedimentation by the analogy with erythrocyte sedimentation rate. 
      RESULTS: The total number of circulating MVs, and particularly the platelet 
      derived CD42+ and PAC-1+ were significantly higher in post-stroke patients (p < 
      0.001). The platelet aggregation in the whole blood (area under the curve, AUC) 
      showed a significant negative correlation with the total number of MPs in the 
      lower blood sample after 1-hour gravity sedimentation (r = -0.650, p = 0.005). 
      Next, we analyzed associations among MPs and aggregometry data obtained from 
      clopidogrel responders and non-responders. Both, area under the curve (AUC) and 
      velocity in the whole blood showed opposite correlation with the total number of 
      MVs in the lower blood sample after 1-hour gravity sedimentation. Importantly, a 
      significant negative correlation was observed for the velocity (r = -0.801, p = 
      0.005), but not for the AUC in responders. Platelet derived CD42+ and PAC-1+ MVs 
      showed positive correlations with neutrophils in the lower blood sample (p = 
      0.008 and p = 0.006 respectively). CONCLUSIONS: Circulating MVs may allow to 
      monitor the response to antiplatelet therapy in post-stroke patients. In 
      addition, the link between platelet derived MVs and neutrophil granulocytes might 
      become therapeutic targets in the future.
CI  - (c) 2022 The Author(s). Published by IMR Press.
FAU - Schrick, Diana
AU  - Schrick D
AD  - Department of Anaesthesiology and Intensive Care, University of Pecs, Medical 
      School, Clinical Centre, 7624 Pecs, Hungary.
FAU - Molnar, Tihamer
AU  - Molnar T
AD  - Department of Anaesthesiology and Intensive Care, University of Pecs, Medical 
      School, Clinical Centre, 7624 Pecs, Hungary.
FAU - Tokes-Fuzesi, Margit
AU  - Tokes-Fuzesi M
AD  - Department of Laboratory Medicine, University of Pecs, Medical School, Clinical 
      Centre, 7624 Pecs, Hungary.
AD  - Central Laboratory, Szigetvar Hospital, 7900 Szigetvar, Hungary.
FAU - Molnar, Abigel
AU  - Molnar A
AD  - Department of Medical Biology and Central Electron Microscopic Laboratory, 
      University of Pecs, Medical School, 7624 Pecs, Hungary.
FAU - Ezer, Erzsebet
AU  - Ezer E
AD  - Department of Anaesthesiology and Intensive Care, University of Pecs, Medical 
      School, Clinical Centre, 7624 Pecs, Hungary.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Singapore
TA  - Front Biosci (Landmark Ed)
JT  - Frontiers in bioscience (Landmark edition)
JID - 101612996
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - A74586SNO7 (Clopidogrel)
SB  - IM
MH  - Blood Platelets/physiology
MH  - *Cell-Derived Microparticles
MH  - Clopidogrel/therapeutic use
MH  - Humans
MH  - *Ischemic Stroke
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - *Stroke/drug therapy
OTO - NOTNLM
OT  - antiplatelet therapy
OT  - clopidogrel
OT  - ischemic stroke
OT  - microvesicles
OT  - neutrophil
OT  - platelet
COIS- The authors declare no conflict of interest.
EDAT- 2022/06/01 06:00
MHDA- 2022/06/03 06:00
CRDT- 2022/05/31 14:54
PHST- 2022/02/08 00:00 [received]
PHST- 2022/04/06 00:00 [revised]
PHST- 2022/04/19 00:00 [accepted]
PHST- 2022/05/31 14:54 [entrez]
PHST- 2022/06/01 06:00 [pubmed]
PHST- 2022/06/03 06:00 [medline]
AID - S2768-6701(22)00508-1 [pii]
AID - 10.31083/j.fbl2705158 [doi]
PST - ppublish
SO  - Front Biosci (Landmark Ed). 2022 May 16;27(5):158. doi: 10.31083/j.fbl2705158.